ValuEngine upgraded shares of Vernalis (OTCMKTS:VNLPY) from a strong sell rating to a sell rating in a research note published on Friday.
Separately, Zacks Investment Research lowered shares of Vernalis from a buy rating to a hold rating and set a $0.25 price objective for the company. in a report on Sunday, January 21st.
Shares of Vernalis (OTCMKTS VNLPY) opened at $0.35 on Friday. Vernalis has a 1-year low of $0.26 and a 1-year high of $0.58.
TRADEMARK VIOLATION NOTICE: “Vernalis (VNLPY) Upgraded to “Sell” at ValuEngine” was published by Stock Observer and is owned by of Stock Observer. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The original version of this report can be accessed at https://www.thestockobserver.com/2018/02/06/vernalis-vnlpy-upgraded-to-sell-at-valuengine.html.
Vernalis Company Profile
Vernalis plc is a commercial-stage pharmaceutical company. The Company is engaged in the research, development and commercialization of pharmaceutical products. The Company operates through two segments: Commercial, which covers all areas relating to the commercial sale of pharmaceutical products, the manufacture and distribution directly related to that activity, and Research and Development, which includes all activities related to the research and development of pharmaceutical products for a range of medical disorders.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Vernalis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vernalis and related companies with MarketBeat.com's FREE daily email newsletter.